These findings suggest that TET2 and ASXL1 mutations may represent early events in the pathogenesis of BPDCN, whereas the other mutations are acquired secondarily due to genomic instability and clonal evolution resulting from epigenetic dysregulation. This evidence concerns the gene TET2 and CD4+/CD56+ hematodermic neoplasm.